Source: Annual Congress 2002 - Asthma - Therapy and management -1
Disease area: Airway diseases

Abstract

AIM(S): The Symbicort Adjustable Maintenance Plan is designed to gain and maintain optimal asthma control with a lower overall dose of budesonide/formoterol combination (B/F; Symbicort® Turbuhaler®) than fixed dosing. METHODS: Patients (mean 48 years, 76% with a duration of asthma >5 years) were administered adjustable maintenance (n=782) with B/F 2 inhalations bid for 4 weeks followed by a step-up or down regimen for 12 weeks (Group A) or fixed B/F dosing (n=771) with 2 inhalations bid for 16 weeks (Group B). The number, type and severity of adverse events (AEs) were recorded. RESULTS: The average daily number of inhalations per patient was 15% lower in Group A compared with Group B. During the 12-week period when patients in Group A could adjust their dose, an equal number of patients in each group reported >=1 AE. There were no unexpected AEs; the majority were considered unrelated to study treatment. Only 2% in each group withdrew due to an AE. The most frequently reported AEs were respiratory infections. Serious AEs occurred in 3% (Group A) and 4% of patients (Group B). CONCLUSIONS: Adjustable maintenance treatment with budesonide/formoterol combination is as well tolerated as fixed dosing and requires a lower overall daily dose.

Rating:

Share or cite this content

Citations should be made in the following way:
P. Ind, J. Haughney, J. P. Rosen, J. Kennelly (London, Aberdeen, Luton, United Kingdom). Managed adjustable dosing of budesonide/formoterol combination is similarly well tolerated to fixed dosing. Eur Respir J 2002; 20: Suppl. 38, 380

Member's Comments

No comment yet.

Related content which might interest you: Managed adjustable dosing of budesonide/formoterol combination provides equivalent asthma control to fixed dosing at a lower overall dose Source: Eur Respir J 2002; 20: Suppl. 38, 396s Year: 2002 Adjustable dosing with budesonide/formoterol in a single inhaler reduces costs compared with a conventional fixed dosing regimen Source: Eur Respir J 2003; 22: Suppl. 45, 411s Year: 2003 Budesonide/formoterol with an adjustable maintenance plan costs less, and is as effective as fixed dosing Source: Eur Respir J 2002; 20: Suppl. 38, 397s Year: 2002 Effectiveness of adjustable maintenance dosing and fixed dosing with budesonide/formoterol single inhaler in a multi-ethnic asthma population Source: Eur Respir J 2004; 24: Suppl. 48, 311s Year: 2004 Scientific rationale for using a single inhaler for asthma control by comparison of the effectiveness and safety of formoterol/budesonide turbuhaler as physician-guided adjustable maintenance dosing regimen versus formoterol/budesonide given as fixed dose of twice daily therapy in the management of bronchial asthma Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009 Adjustable maintenance dosing with budesonide/formoterol provides effective asthma symptom control at a lower average dose than with fixed dosing – 6-month study Source: International Congress 2018 – Asthma and drugs Year: 2018 Benefits of adjustable versus fixed maintenance dosing of budesonide/formoterol: a Swiss study in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 258s Year: 2003 Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with fixed dosing – 3-month study Source: International Congress 2017 – Clinical points to ponder in asthma Year: 2017 Adjustable maintenance dosing with budesonide/formoterol provides effective asthma symptom control at a lower average dose than fixed dosing: results of a study in Italy Source: Eur Respir J 2003; 22: Suppl. 45, 411s Year: 2003 Budesonide/formoterol adjustable maintenance dosing and fixed dosing in adolescents with asthma: a Swedish study Source: Eur Respir J 2003; 22: Suppl. 45, 258s Year: 2003 Adjustable dosing with budesonide/formoterol in a single inhaler maintains improvement in health-related quality of life at a lower drug load than fixed dosing – the ATACO study Source: Eur Respir J 2003; 22: Suppl. 45, 258s Year: 2003 Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with fixed dosing – a 5-month study in Canada Source: Eur Respir J 2003; 22: Suppl. 45, 411s Year: 2003 Maintenance plus as-needed budesonide/formoterol is cost-effective compared with dose-titrated salmeterol/fluticasone Source: Eur Respir J 2005; 26: Suppl. 49, 50s Year: 2005 Comparison of two twice-daily doses of budesonide/formoterol maintenance and reliever therapy Source: Eur Respir J 2010; 36: 524-530 Year: 2010 Adjustable dosing with budesonide/formoterol achieves sustained guideline ‘well-controlled asthma‘ following step down in treatment Source: Eur Respir J 2005; 26: Suppl. 49, 50s Year: 2005 The ATACO study: adjustable maintenance therapy with budesonide and formoterol in a single inhaler Source: Eur Respir J 2002; 20: Suppl. 38, 41s Year: 2002 Fewer asthma patients experience exacerbations with budesonide/formoterol in a single inhaler using adjustable versus fixed dosing Source: Eur Respir J 2003; 22: Suppl. 45, 438s Year: 2003 Budesonide/formoterol single inhaler therapy is well tolerated and reduces systemic steroid use Source: Eur Respir J 2004; 24: Suppl. 48, 310s Year: 2004 4-month adjustable or fixed maintenance treatment with budesonide/formoterol in a single inhaler reduces symptom severity Source: Eur Respir J 2002; 20: Suppl. 38, 41s Year: 2002 Safety and tolerability of the novel very long acting β2-agonist Carmoterol given as a 2μg qd dose; 8 days comparison with formoterol and placebo in patients with persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 665s Year: 2006